Table 3.

Patient baseline risk category according to the NCEP ATP III 2004 updated guidelines; the number of patients in each risk category obtaining their treatment goals, overall and according to statin prescribed

Patient characteristics	Risk category	LDL-C target	Number of patients at baseline, n (%)	Patients achieving treatment goal, n (%)	Patients achieving treatment goal according to prescribed statin, n (%) [mean dose, mg ± SD]
All patients	All			339 (32.5)	Atorvastatin: 135 (28.1) [17.6 ± 10.2] Simvastatin: 46 (33.8) [22.0 ± 11.1] Rosuvastatin: 135 (39.0) [13.3 ± 4.7] Fluvastatin:4 (20.0) [NA] Pravastatin:3 (37.5) [NA]
Established CVD plus diabetes, smoker, low HDL-C and high triglycerides, metabolic syndrome or multiple risk factors (see definition below)	Very high	<70 mg/dL (1.81 mmol/L)	393 (37.7)	42 (10.7)	Rosuvastatin: 14 (11.4) [NA] Atorvastatin: 21 (10.4) [NA] Simvastatin: 4 (8.9) [NA]
CHD, or CHD risk equivalents, or Framingham 10-year risk >20%	High	<100 mg/dL (2.59 mmol/L)	362 (34.7)	124 (34.2)	Rosuvastatin: 46 (49.0) [NA] Atorvastatin: 53 (40.0) [NA] Simvastatin: 20 (45.6) [NA]
>2 risk factors with Framingham 10-year risk between 10% and 20%	Medium high	<100 mg/dL (2.59 mmol/L)	38 (3.6)	3 (7.9)	Rosuvastatin: 1 (9.1) [NA] Atorvastatin: 1 (6.2) [NA] Simvastatin: 1 (20.0) [NA]
>2 risk factors with Framingham 10-year risk <10%	Medium low	<130 mg/dL (3.36 mmol/L)	167 (16.0)	111 (66.5)	Rosuvastatin: 47 (78.2) [NA] Atorvastatin: 42 (65.6) [NA] Simvastatin: 14 (51.8) [NA]
0–1 risk factor	Low	<160 mg/dL (4.14 mmol/L)	83 (8.0)	59 (71.1)	Rosuvastatin: 27 (79.4) [NA] Atorvastatin: 18 (64.3) [NA] Simvastatin: 7 (58.3) [NA]

CHD coronary heart disease, CVD cardiovascular disease, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NCEP ATP III National Cholesterol Education Program Adult Treatment Panel III, NA not available, SBP systolic blood pressure, SD standard deviation